These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30445988)

  • 1. Effect of a high-protein diet with β-cryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial.
    Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K
    Trials; 2018 Nov; 19(1):634. PubMed ID: 30445988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An energy-restricted high-protein diet supplemented with β-cryptoxanthin alleviated oxidative stress and inflammation in nonalcoholic fatty liver disease: a randomized controlled trial.
    Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K
    Nutr Res; 2020 Jan; 73():15-26. PubMed ID: 31841744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
    Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
    Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
    Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of DASH diet on weight loss and metabolic status in adults with non-alcoholic fatty liver disease: a randomized clinical trial.
    Razavi Zade M; Telkabadi MH; Bahmani F; Salehi B; Farshbaf S; Asemi Z
    Liver Int; 2016 Apr; 36(4):563-71. PubMed ID: 26503843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial.
    Ebrahimpour-Koujan S; Sohrabpour AA; Foroughi F; Alvandi E; Esmaillzadeh A
    Trials; 2019 Mar; 20(1):153. PubMed ID: 30832722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose homeostasis, insulin resistance and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: Beneficial effects of supplementation with microalgae Chlorella vulgaris: A double-blind placebo-controlled randomized clinical trial.
    Ebrahimi-Mameghani M; Sadeghi Z; Abbasalizad Farhangi M; Vaghef-Mehrabany E; Aliashrafi S
    Clin Nutr; 2017 Aug; 36(4):1001-1006. PubMed ID: 27475283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial.
    Haidari F; Hojhabrimanesh A; Helli B; Seyedian SS; Ahmadi-Angali K; Abiri B
    BMC Gastroenterol; 2020 Oct; 20(1):349. PubMed ID: 33081717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors in adults with central obesity: study protocol for a randomised controlled study.
    Zhou J; Zhao D; Wang N; Zeng Z; Wang C; Hao L; Peng X
    Trials; 2020 Jan; 21(1):32. PubMed ID: 31907080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fish oil supplementation on the concentration of miRNA-122, FGF-21 and liver fibrosis in patients with NAFLD: Study protocol for a randomized, double-blind and placebo-controlled clinical trial.
    Barroso LN; Salarini J; Leite NC; Villela-Nogueira CA; Dávalos A; Carmo MDGT; Ferreira Peres WA
    Clin Nutr ESPEN; 2023 Oct; 57():117-125. PubMed ID: 37739645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effect of curcumin and zinc co-supplementation on glycemic measurements, lipid profiles, and inflammatory and antioxidant biomarkers in overweight or obese prediabetic patients: a study protocol for a randomized double-blind placebo-controlled phase 2 clinical trial.
    Karandish M; Mozaffari-Khosravi H; Mohammadi SM; Azhdari M; Cheraghian B
    Trials; 2020 Nov; 21(1):991. PubMed ID: 33256795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial.
    Lorvand Amiri H; Agah S; Tolouei Azar J; Hosseini S; Shidfar F; Mousavi SN
    Clin Nutr; 2017 Dec; 36(6):1490-1497. PubMed ID: 27720403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation.
    Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M
    Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
    Barchetta I; Del Ben M; Angelico F; Di Martino M; Fraioli A; La Torre G; Saulle R; Perri L; Morini S; Tiberti C; Bertoccini L; Cimini FA; Panimolle F; Catalano C; Baroni MG; Cavallo MG
    BMC Med; 2016 Jun; 14():92. PubMed ID: 27353492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of green coffee extract supplementation on serum adiponectin concentration and lipid profile in patients with non-alcoholic fatty liver disease: A randomized, controlled trial.
    Hosseinabadi S; Rafraf M; Asghari S; Asghari-Jafarabadi M; Vojouhi S
    Complement Ther Med; 2020 Mar; 49():102290. PubMed ID: 32147076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes.
    Tutunchi H; Ostadrahimi A; Saghafi-Asl M; Hosseinzadeh-Attar MJ; Shakeri A; Asghari-Jafarabadi M; Roshanravan N; Farrin N; Naemi M; Hasankhani M
    Pharmacol Res; 2020 Jun; 156():104770. PubMed ID: 32217148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial.
    Hallsworth K; Thoma C; Hollingsworth KG; Cassidy S; Anstee QM; Day CP; Trenell MI
    Clin Sci (Lond); 2015 Dec; 129(12):1097-105. PubMed ID: 26265792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.